Daniel E M, Stoner G D
Department of Pathology, Medical College of Ohio, Toledo 43699.
Cancer Lett. 1991 Feb;56(2):117-24. doi: 10.1016/0304-3835(91)90085-v.
Ellagic acid (EA) and 13-cis-retinoic acid (CRA), both alone and in combination, were tested for their ability to inhibit N-nitrosobenzylmethylamine-induced tumors in the rat esophagus. Groups of male rats were fed AIN-76A diet containing EA (4 g/kg), CRA (240 mg/kg), or a combination of EA and CRA (4 g/kg and 240 mg/kg), respectively, for 25 weeks. Two weeks after initiation of the diets, NBMA (0.5 mg/kg per injection) was administered s.c. once weekly for 15 weeks. After 25 weeks on the diets, the animals were necropsied. The incidence of esophageal tumors was 97-100% in all NBMA-treated groups. The multiplicity of tumors in NBMA-treated groups was reduced significantly by EA (60%), but not by CRA, or by EA + CRA. These results demonstrate that EA and CRA do not act synergistically to inhibit NBMA-induced esophageal tumorigenesis.
对鞣花酸(EA)和13 - 顺式维甲酸(CRA)单独及联合使用时抑制大鼠食管中N - 亚硝基苄基甲胺诱导肿瘤的能力进行了测试。将雄性大鼠分组,分别喂食含EA(4 g/kg)、CRA(240 mg/kg)或EA与CRA组合(4 g/kg和240 mg/kg)的AIN - 76A饮食,持续25周。在开始饮食两周后,每周一次皮下注射NBMA(0.5 mg/kg),共注射15周。在饮食25周后,对动物进行尸检。所有接受NBMA治疗的组中食管肿瘤的发生率为97 - 100%。EA可使NBMA治疗组的肿瘤多发性显著降低(60%),但CRA或EA + CRA则无此效果。这些结果表明,EA和CRA在抑制NBMA诱导的食管肿瘤发生方面不存在协同作用。